文献速递肝病

AZD2693(一种PNPLA3反义寡核苷酸)治疗148M纯合子受试者MASH:两项随机I期试验

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.
PubMed 文献 · J Hepatol · 2025-01-09

两项随机I期试验评估了靶向PNPLA3 mRNA的反义寡核苷酸AZD2693在健康志愿者及MRI-PDFF≥7%受试者中的安全性、药代动力学和药效学。单次递增剂量研究为2-110 mg,多次递增剂量研究为每月25 mg、50 mg、80 mg共三次。AZD2693总体耐受良好,半衰期14-33天,80 mg剂量下肝脏PNPLA3 mRNA敲低89%,第12周肝脏脂肪含量在25 mg和50 mg剂量下分别较安慰剂校正后降低7.6%和12.2%。

要点

  • AZD2693在健康志愿者及MRI-PDFF≥7%受试者中总体耐受良好,未出现导致停药的不良事件或治疗相关严重不良事件。
  • 80 mg剂量下肝脏PNPLA3 mRNA最小二乘均值敲低89%,并降低蛋白水平,证实靶点结合。
  • 第12周肝脏脂肪含量安慰剂校正后最小二乘均值变化:25 mg剂量降低7.6%,50 mg剂量降低12.2%。

核心结论

  • AZD2693降低了肝脏PNPLA3,安全性和耐受性可接受,这些发现支持继续开发AZD2693。
  • 作者认为这些数据支持继续开发AZD2693作为MASH的潜在精准医学治疗,IIb期FORTUNA研究正在进行中。

研究设计与样本

  • 在PNPLA3 148M纯合子原代人肝细胞3D培养和表达人PNPLA3的小鼠中评估AZD2693。
  • 单次递增剂量研究在超重/轻度肥胖但其他方面健康的志愿者中考察2-110 mg剂量。
  • 多次递增剂量研究在MRI-质子密度脂肪分数(MRI-PDFF)≥7%的受试者中考察每月三次剂量(25 mg、50 mg和80 mg)。
  • 通过MRI-PDFF在基线、第8周和第12周评估肝脏脂肪含量变化,并对80 mg剂量评估PNPLA3 mRNA和蛋白敲低水平。

主要发现

  • AZD2693在人间肝细胞和小鼠肝脏中强效降低PNPLA3表达。
  • 临床上半衰期在所研究的剂量范围内为14-33天。
  • 80 mg剂量下肝脏PNPLA3 mRNA最小二乘均值敲低89%,蛋白水平降低,证实靶点结合。
  • 第12周肝脏脂肪变性变化(安慰剂校正最小二乘均值):25 mg剂量为-7.6%,50 mg剂量为-12.2%。
  • 血清甘油三酯中多不饱和脂肪酸呈剂量依赖性增加,高敏C反应蛋白和白细胞介素6较安慰剂降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A common genetic variant (rs738409) encoding an isoleucine to methionine substitution at position 148 in the PNPLA3 protein is a determinant of hepatic steatosis, inflammation, fibrosis, cirrhosis, and liver-related mortality. AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA. We evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics in single and multiple ascending dose studies. METHODS: AZD2693 was assessed in 3D cultures of homozygous PNPLA3 148M primary human hepatocytes and mice expressing human PNPLA3. The single ascending dose study investigated 2-110 mg doses in overweight/mildly obese but otherwise healthy volunteers. The multiple ascending dose study investigated three monthly doses (25 mg, 50 mg and 80 mg) in participants with MRI-proton density fat fraction (MRI-PDFF) ≥7%. Changes in liver fat content were assessed at baseline, weeks 8 and 12 by MRI-PDFF. PNPLA3 mRNA and protein knockdown levels were evaluated for the 80 mg dose. RESULTS: AZD2693 potently reduced PNPLA3 expression in human hepatocytes and livers of mice. Clinically, AZD2693 was generally well tolerated (no adverse events leading to discontinuation or treatment-related serious adverse events). Half-life was 14-33 days across investigated doses. A least-square mean liver PNPLA3 mRNA knockdown of 89% and reduction of protein levels demonstrated target engagement. Changes in hepatic steatosis at week 12 were -7.6% and -12.2% (placebo-corrected least-square means) for the 25 mg and 50 mg doses, respectively. There was a dose-dependent increase of polyunsaturated fatty acids in serum triglycerides and decreases vs. placebo in high-sensitivity C-reactive protein and interleukin 6. CONCLUSIONS: AZD2693 reduced liver PNPLA3 with an acceptable safety and tolerability profile. These findings support the continued development of AZD2693. IMPACT AND IMPLICATIONS: Clinical treatment options for metabolic dysfunction-associated steatohepatitis (MASH) are limited. The genetic risk factor with the largest effect size for progressing to poor liver-related outcomes in MASH is a single-nucleotide polymorphism in the gene PNPLA3 (p.I148M). In phase I single and multiple ascending dose studies, AZD2693, a liver-targeted antisense oligonucleotide, was well tolerated, reduced liver PNPLA3 mRNA and protein levels, and dose-dependently reduced liver fat content in homozygous PNPLA3 148M risk allele carriers. These data support continued development of AZD2693 as a potential precision medicine treatment for MASH. The phase IIb FORTUNA study is now ongoing. CLINICAL TRIAL NUMBER: NCT04142424, NCT04483947.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Armisen J, Rauschecker M, Sarv J, et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials. J Hepatol. 2025. PMID: 39798707. doi:10.1016/j.jhep.2024.12.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。